SCHEDULE 13G/A: Venrock Healthcare Entities Maintain 1.5% Stake in 4D Molecular Therapeutics

Venrock Healthcare Capital Partners and affiliated entities have filed an amended Schedule 13G, disclosing a continued beneficial ownership of 1.5% in 4D Molecular Therapeutics, Inc. as of March 31, 2025.

Summary

• Venrock Healthcare Capital Partners III, L.P., VHCP Co-Investment Holdings III, LLC, Venrock Healthcare Capital Partners EG, L.P., VHCP Management III, LLC, VHCP Management EG, LLC, Nimish Shah, and Bong Koh collectively reported beneficial ownership of 677,600 shares of Common Stock in 4D Molecular Therapeutics, Inc.
• This aggregate ownership represents 1.5% of the Issuer's Common Stock outstanding as of March 31, 2025.
• The percentage is based on 46,302,407 shares of Common Stock outstanding as of February 26, 2025, as reported in the Issuer's Annual Report on Form 10-K filed on February 28, 2025.
• The shares are held across three entities: VHCP III (169,979 shares), VHCP Co-Investment III (17,007 shares), and VHCP EG (490,614 shares).
• VHCP Management III is the general partner of VHCP III and the manager of VHCP Co-Investment III, while VHCP Management EG is the general partner of VHCP EG.
• Messrs. Shah and Koh are the voting members of both VHCP Management III and VHCP Management EG, and thus share voting and dispositive power over the reported shares.
• The reporting persons explicitly state that the securities were not acquired and are not held for the purpose or effect of changing or influencing the control of the issuer.

Sentiment

Score: 5

Explanation: The document is a standard regulatory filing (Schedule 13G amendment) disclosing beneficial ownership. It is neutral in tone and content, providing factual information without expressing positive or negative sentiment about the issuer's performance or prospects. The continued ownership by a significant investor is a neutral to slightly positive signal, but the document itself is purely informational.

Positives

• The continued beneficial ownership by Venrock Healthcare Capital Partners and its affiliates may signal ongoing confidence in 4D Molecular Therapeutics, Inc. from a significant institutional investor.

Negatives

• NA

Risks

• The filing itself does not detail specific risks related to 4D Molecular Therapeutics, Inc.'s operations or financial health, as it is a beneficial ownership report.

Future Outlook

This Schedule 13G filing does not contain any forward-looking statements or guidance regarding the future outlook of 4D Molecular Therapeutics, Inc. or the reporting persons' investment strategy beyond the current ownership disclosure.

Industry Context

This filing is a routine disclosure of beneficial ownership by an institutional investor in a biotechnology company. It does not provide specific insights into broader industry trends or competitive landscape, but it highlights continued investment interest in the gene therapy sector, where 4D Molecular Therapeutics operates.

Stakeholder Impact

• Shareholders: Provides transparency regarding the ownership structure and the continued stake held by a notable institutional investor group, which can influence investor perception and confidence.

Key Dates

Keywords

4D Molecular Therapeutics, Venrock Healthcare Capital Partners, Schedule 13G, Beneficial Ownership, Common Stock, Institutional Investor, SEC Filing, Biotechnology, Gene Therapy